Clinical Trials
5 trialsNCT05812807 2026-06-05
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
Alliance for Clinical Trials in Oncology
Phase 3 Recruiting
NCT02954874 2026-06-03
Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT05333874 2026-02-09
CIPHER Study: Pilot Study to Study the Role of ctDNA in Triple Negative and HER2 Positive Early Stage
Rutgers, The State University of New Jersey
Phase EARLY_PHASE1 Active not recruiting
NCT07262138 2025-12-03
ACTIVE
University of Pittsburgh
Recruiting
NCT03418961 2025-10-08
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
SWOG Cancer Research Network
Phase 3 Recruiting